Use of avacopan in granulomatosis with polyangiitis with predominant gastrointestinal and kidney involvement
{{output}}
Avacopan, an oral C5a receptor 1 antagonist, is approved as a glucocorticoid-sparing option for remission induction in antineutrophil cytoplasmic antibody-associated vasculitis. Since April 2026, its marketing authorisation is undergoing regulatory review by t... ...
